Skin Analytics

Skin Analytics, founded in 2012, is a UK-based startup revolutionizing skin cancer detection with its AI medical device, DERM. The company's mission to eliminate skin cancer deaths is evident in its partnership with 18 NHS dermatology teams, deploying AI-powered skin cancer pathways. DERM, the first and only AI skin cancer pathway within the NHS, is a Class IIa UKCA marked and Class III CE marked AI medical device, having identified over 13,000 cancers in pathways that have served more than 135,000 NHS patients. The company's commitment to improving patient outcomes and sustainability is underscored by its impact on NHS organizations, enabling them to discharge benign lesions earlier, thus addressing backlog, reducing out-patient delays, and prioritizing patients in need of life-saving treatment. Skin Analytics' impressive track record, including a Series B investment of €17.50M led by Intrepid Growth Partners on 16 April 2025, speaks to its significant potential in the AI, Analytics, Digital Health, Health Care, and Machine Learning industries. Additionally, the company's provision of remote skin assessment services to Bupa and Vitality signifies its commitment to expanding access to advanced skin care solutions.